EP Patent

EP1153920A1 — Quinoline derivatives and quinazoline derivatives

Assigned to Kirin Brewery Co Ltd · Expires 2001-11-14 · 25y expired

What this patent protects

An object of the present invention is to provide compounds which have antitumor activity and do not change cytomorphosis. Disclosed are compounds represented by formula (I) and a pharmaceutically acceptable salts and solvates thereof and pharmaceutical compositions comprising sai…

USPTO Abstract

An object of the present invention is to provide compounds which have antitumor activity and do not change cytomorphosis. Disclosed are compounds represented by formula (I) and a pharmaceutically acceptable salts and solvates thereof and pharmaceutical compositions comprising said compounds: wherein X and Z each independently represent CH or N; R 1 to R 3 represent H, substituted alkoxy, unsubstituted alkoxy or the like; R 4 represents H; R 5 to R 8 represent H, halogen, alkyl, alkoxy, alkylthio, nitro, or amino, provided that R 5 to R 8 do not simultaneously represent H; R 9 and R 10 represent H, alkyl, or alkylcarbonyl; and R 11 represents alkyl, alkenyl, alkynyl, or aralkyl.

Drugs covered by this patent

Patent Metadata

Patent number
EP1153920A1
Jurisdiction
EP
Classification
Expires
2001-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Kirin Brewery Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.